HIV-associated Lipodystrophy -Epidemiology Forecast to 2027

HIV-associated Lipodystrophy -Epidemiology Forecast to 2027

Category

Pharmaceuticals

Published Date

1st Feb 2018

Pages

50

Choose License

Final Price

DelveInsight's "HIV-associated Lipodystrophy - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the HIV-associated Lipodystrophy epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2027

HIV-associated Lipodystrophy Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for HIV-associated Lipodystrophy in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the HIV-associated Lipodystrophy outlook. It also includes the explanation of changing trends of epidemiology outlining the HIV-associated Lipodystrophy scenario.

HIV-associated Lipodystrophy Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the HIV-associated Lipodystrophy thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of HIV-associated Lipodystrophy explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The HIV-associated Lipodystrophy Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in HIV-associated Lipodystrophy

Key assessments
• Patient Segmentation in HIV-associated Lipodystrophy
• HIV-associated Lipodystrophy Risk & Burden
• Factors driving growth in a specific HIV-associated Lipodystrophy patient population
1. Report Introduction
2. HIV-associated Lipodystrophy Epidemiology Overview at a Glance
2.1. Patient Share Distribution of HIV-associated Lipodystrophy in 2017
2.2. Patient Share Distribution of HIV-associated Lipodystrophy in 2027
3. Disease Background and Overview: HIV-associated Lipodystrophy
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of HIV-associated Lipodystrophy in 7MM
4.3. Total Prevalent/ Incident Patient Population of HIV-associated Lipodystrophy in 7MM – By Countries
5. Epidemiology of HIV-associated Lipodystrophy by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.1.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy *
5.1.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.1.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.4.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.4.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.4.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.5.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.5.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.5.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.6.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.6.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.6.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.7.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.7.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.7.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.8.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.8.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.8.5. Diagnosed Cases of the HIV-associated Lipodystrophy
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the HIV-associated Lipodystrophy
5.9.3. Sub-Type Specific cases of the HIV-associated Lipodystrophy*
5.9.4. Sex- Specific Cases of the HIV-associated Lipodystrophy*
5.9.5. Diagnosed Cases of the HIV-associated Lipodystrophy
6. Unmet Needs of the HIV-associated Lipodystrophy
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific
Table 1: Total Prevalent/Incident Cases of the HIV-associated Lipodystrophy in 7MM
Table 2: Total Prevalent/Incident Cases of the HIV-associated Lipodystrophy in 7MM by Countries
Table 3: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in United States (2016-2027)
Table 4: Sub-Type Specific cases of the HIV-associated Lipodystrophy in United States (2016-2027)*
Table 5: Sex- Specific Cases of the HIV-associated Lipodystrophy in United States (2016-2027)*
Table 6: Diagnosed Cases of the HIV-associated Lipodystrophy in United States (2016-2027)
Table 7: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Germany (2016-2027)
Table 8: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Germany (2016-2027) *
Table 9: Sex- Specific Cases of the HIV-associated Lipodystrophy in Germany (2016-2027) *
Table 10: Diagnosed Cases of the HIV-associated Lipodystrophy in Germany (2016-2027)
Table 11: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in France (2016-2027)
Table 12: Sub-Type Specific cases of the HIV-associated Lipodystrophy in France (2016-2027) *
Table 13: Sex- Specific Cases of the HIV-associated Lipodystrophy in France (2016-2027) *
Table 14: Diagnosed Cases of the HIV-associated Lipodystrophy in France (2016-2027)
Table 15: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Italy (2016-2027)
Table 16: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Italy (2016-2027) *
Table 17: Sex- Specific Cases of the HIV-associated Lipodystrophy in Italy (2016-2027) *
Table 18: Diagnosed Cases of the HIV-associated Lipodystrophy in Italy (2016-2027)
Table 19: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Spain (2016-2027)
Table 20: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Spain (2016-2027) *
Table 21: Sex- Specific Cases of the HIV-associated Lipodystrophy in Spain (2016-2027) *
Table 22: Diagnosed Cases of the HIV-associated Lipodystrophy in Spain (2016-2027)
Table 23: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in UK (2016-2027)
Table 24: Sub-Type Specific cases of the HIV-associated Lipodystrophy in UK (2016-2027) *
Table 25: Sex- Specific Cases of the HIV-associated Lipodystrophy in UK (2016-2027) *
Table 26: Diagnosed Cases of the HIV-associated Lipodystrophy in UK (2016-2027)
Table 27: Prevalent/Incident Cases of the HIV-associated Lipodystrophy in Japan (2016-2027)
Table 28: Sub-Type Specific cases of the HIV-associated Lipodystrophy in Japan (2016-2027) *
Table 29: Sex- Specific Cases of the HIV-associated Lipodystrophy in Japan (2016-2027) *
Table 30: Diagnosed Cases of the HIV-associated Lipodystrophy in Japan (2016-2027)

Get Free Sample

You can get a FREE sample of any report. Just click the "Free Sample" link.

Explore Latest Reports

If you have any special requirement or looking for more discounts, Kindly contact our sales team

Contact Us